Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance

Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance

Approximately 10% of non–small cell lung cancer (NSCLC) patients in the United States and 40% of NSCLC patients in Asia have activating epidermal growth factor receptor (EGFR) mutations and are eligible to receive targeted anti-EGFR therapy. Despite an extension of life expectancy associated with th...

Full description

Bibliographic Details
Main Authors: Moores, Sheri L., Laquerre, Sylvie, Emdal, Kristina Bennet, Dittmann, Antje, Reddy, Raven J., Lescarbeau, Rebecca S., White, Forest M.
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Published: American Association for Cancer Research (AACR) 2018
Online Access:http://hdl.handle.net/1721.1/119191
https://orcid.org/0000-0001-6483-9110
https://orcid.org/0000-0002-2570-5192
https://orcid.org/0000-0002-3856-7454
https://orcid.org/0000-0003-2409-4315
https://orcid.org/0000-0002-1545-1651

Internet

http://hdl.handle.net/1721.1/119191
https://orcid.org/0000-0001-6483-9110
https://orcid.org/0000-0002-2570-5192
https://orcid.org/0000-0002-3856-7454
https://orcid.org/0000-0003-2409-4315
https://orcid.org/0000-0002-1545-1651

Similar Items